13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001616824
Total reported value
$175.7M
$175.7M
25 檔
60.0%
The Q4 2024 SEC filing reveals that BML Capital Management, LLC held a total portfolio value of $175.7M, covering 25 public equity positions.
During Q4 2024, BML Capital Management, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ACRS | Aclaris Therapeutics Inc | Stock-Other | 21.95% | +1.74% | — | |
| 2 | SGOV | Ishares 0-3 Month Treasury B | ETF-Gov Bonds | 16.20% | — | -3.70% | |
| 3 | AVIR | Atea Pharmaceuticals Inc | Stock-Other | 15.83% | -5.98% | +14.41% | |
| 4 | AVU0 | Adverum Biotechnologies Inc | Stock-Other | 6.58% | — | — | |
| 5 | ANTX | An2 Therapeutics Inc | Stock-Other | 4.93% | — | — | |
| 6 | TIL | Instil Bio Inc | Stock-Other | 4.74% | -0.59% | +19.40% | |
| 7 | EPIEUR | Essa Pharma Inc | Stock-Other | 4.69% | — | — | |
| 8 | WHWK | Whitehawk Therapeutics Inc | Stock-Other | 4.12% | — | +5.00% | |
| 9 | ORMP | Oramed Pharmaceuticals Inc | Stock-Other | 3.97% | -4.54% | +20.94% | |
| 10 | ✓ | Ikena Oncology Inc | Stock-Other | 3.65% | — | +395.77% | |
| 11 | PMVP | Pmv Pharmaceuticals Inc | Stock-Other | 3.25% | -0.18% | +105.28% | |
| 12 | 698 | Achilles Therapeutics Pl-adr | Stock-Other | 2.90% | — | — | |
| 13 | CNTB | Connect Biopharma Holdings Limited | Stock-Other | 1.79% | — | — | |
| 14 | MIST | Milestone Pharmaceuticals In | Stock-Other | 1.67% | — | — | |
| 15 | ✓ | Athira Pharma Inc | Stock-Other | 1.01% | — | — | |
| 16 | ASTC | Astrotech CORP | Stock-Other | 0.92% | — | — | |
| 17 | LSTA | Lisata Therapeutics Inc | Stock-Other | 0.53% | — | — | |
| 18 | PVLA | Palvella Therapeutics Inc | Stock-Other | 0.31% | — | — | |
| 19 | VTGN | Vistagen Therapeutics Inc | Stock-Other | 0.27% | — | — | |
| 20 | 2KZ0 | Kezar Life Sciences Inc | Stock-Other | 0.20% | -3.43% | EXIT | |
| 21 | LENZ | Lenz Therapeutics Inc | Stock-Other | 0.17% | — | -84.55% | |
| 22 | NXTCEUR | Nextcure Inc | Stock-Other | 0.13% | — | -1.06% | |
| 23 | ✓ | Verrica Pharmaceuticals Inc | Stock-Other | 0.08% | — | -2.97% | |
| 24 | ✓ | Stock-Other | 0.05% | — | -69.45% | ||
| 25 | ✓ | Hillevax Inc | Stock-Other | 0.03% | — | +5.06% |
According to official SEC Form 13F filings, BML Capital Management, LLC reported a total U.S. public equity portfolio value of $175.7M across 25 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ACRS, SGOV, AVIR) accounted for 60.0% of total reported equity market value during Q4 2024.
During Q4 2024, BML Capital Management, LLC's top holdings by market value included ACRS (21.9%)、SGOV (16.2%)、AVIR (15.8%). The largest single position, ACRS, represented 21.9% of total portfolio value.
In Q4 2024, BML Capital Management, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.